Genomatica brings its naturally sourced Brontide(TM) butylene glycol to Europe
Azelis chosen to distribute; already confirming better personal care formulations
SAN DIEGO and ANTWERP, Belgium, March 20, 2018 (GLOBE NEWSWIRE) -- Genomatica, a widely-recognized technology leader for naturally sourced chemicals, and Azelis, a leading distributor of specialty chemicals, announced that Azelis is now the exclusive distributor for personal care applications of Genomatica's naturally sourced, award-winning Brontide(TM) butylene glycol in Europe. Azelis is already seeing widespread interest in Brontide from major brands and plans to support scores of major customers during Brontide's market introduction. See Brontide introduction video.
Photos accompanying this announcement are available at
A naturally sourced, sustainable cosmetics ingredient; Brontide honored for innovation
Butylene glycol, a colorless organic alcohol, is commonly used in a wide range of personal care products to increase moisture retention (as a humectant), improve texture, and provide antimicrobial properties. Additionally, it is used to evenly disperse plant extracts, flavors and fragrances.
Genomatica produces Brontide biobased butylene glycol from natural, plant-based sugars using its safe and sustainable fermentation-based process technology. This innovative approach has high appeal in personal care applications where demand for natural ingredients is growing. Brontide has already been recognized by the mainstream chemical industry with the prestigious ICIS Innovation Award.
Azelis actively developing formulations; sees strong customer interest
Azelis, a leading global specialty chemicals distributor with over 40,000 customers in 40 countries will provide sales, technical and logistics support for personal care product makers in Europe that are looking for a natural alternative to petroleum-based butylene glycol.
Azelis has also been actively developing and testing multiple personal care product formulations using Genomatica's Brontide, including hydra gels, body sprays, and sunscreens. These have tested well for key formulation attributes such as scent, viscosity, pH and stability.
Azelis reports that demand for natural ingredients has multiplied across its customer base. "We're already seeing strong interest in Genomatica's Brontide butylene glycol," said Tony Craske, Market Segment Director EMEA for Personal Care, Azelis. "Brontide is a perfect example of the new and exciting technologies that we deliver to our personal care partners. This naturally sourced, sustainable high-quality ingredient makes it easy for formulators and brands to improve their products."
"Azelis knows how to highlight the value of a great ingredient and help their customers benefit from it," said Damien Perriman, Genomatica's Senior Vice President, Specialty Chemicals. "Together, we can help make lots of everyday products better for people and the planet."
Genomatica has been producing and shipping tons of Brontide to customers since mid-2017. For samples, companies developing personal care products in Europe should contact Azelis at Brontide.BG@azelis.com; all others should contact Genomatica at Brontide@genomatica.com.
Azelis is a leading distributor of speciality chemicals and food ingredients present in over 40 countries across the globe with around 1,800 employees. Our knowledgeable teams of industry, market and technical experts are each dedicated to a specific market within Life Sciences and Industrial Chemicals. We offer a lateral value chain of complementary products to over 40,000 customers, creating a turnover of €1.8 billion. In the US we operate under a number of renowned co-brands that cater to the various markets in the region.
Throughout our extensive network of 39 application laboratories, our award-winning technical staff help customers develop formulations. We combine a global reach with a local focus to offer a reliable, integrated service to local customers and attractive business opportunities to principals. And we believe in building and nurturing solid, honest and transparent relationships with our people and partners.
Creating value, growing together. www.azelis.com
Genomatica is a widely-recognized leader in bioengineering. It develops biobased process technologies that enable a better way to produce widely-used chemicals, from alternative feedstocks, with better economics, sustainability and performance. Genomatica has earned widespread acclaim for its technology and commercialization achievements. Awards include the Kirkpatrick Award, for "the most noteworthy chemical engineering technology commercialized in the world" and the ICIS Innovation Award for its Brontide(TM) butylene glycol. To learn more, visit www.genomatica.com.
For more information
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Genomatica via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
SpeeDx and Serosep sign UK and Ireland distribution agreement23.4.2018 07:00 | Pressemelding
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed Plex PCR ® and Resistance Plus ® molecular diagnostic tests across the region. The agreement provides Serosep customers with access to SpeeDx's proprietary technology for infectious disease diagnostics, in line with Serosep's goal of improving lives while supporting the everyday struggles faced by laboratories. The SpeeDx portfolio includes the market-leading Resistance Plus MG assay - for simultaneous detection of Mycoplasma genitalium and genetic markers for azithromycin resistance - as well as a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis). Further Resistance Plus assays will be released later this year - including a test for gonorrhoea - along with a comprehensive Plex PCR multiplex p
Winners in 2018 Asia-Pacific Stevie® Awards Announced23.4.2018 04:00 | Pressemelding
Honorees for Innovation in Business to Be Recognized in Hong Kong on 1 June FAIRFAX, Va., April 22, 2018 (GLOBE NEWSWIRE) -- Winners in the fifth annual Asia-Pacific Stevie® Awards, the only awards program to recognize innovation in business throughout the entire Asia-Pacific region, were announced today. The list of Gold, Silver and Bronze Stevie Award winners is available at http://Asia.StevieAwards.com. The Stevie Awards are considered to be the world's premier business awards, conferring recognition for achievement in the workplace over the past 16 years in programs such as The International Business Awards® and The American Business Awards®. The 2018 Asia-Pacific Stevie Awards have recognized organizations in 14 nations including Australia, China, India, Indonesia, Japan, Malaysia, Myanmar, Philippines, Singapore, South Korea, Taiwan, Thailand, the U.S.A. and Vietnam. More than 800 nominations about innovative achievements in the 22-nation APAC region were considered by the judges
Gratomic and Perpetuus Carbon Technologies Limited Enter Into an Agreement for the Exclusive Development and Marketing of Material Enhancing Graphenes Derived From Gratomic Aukam Graphite22.4.2018 22:00 | Pressemelding
TORONTO, April 22, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. ("GRAT" or the "Company") (TSX-V:GRAT) (FRANKFURT:CB81) (WKN:A2JAP3). Gratomic Inc., is pleased to announce that the Company has signed a letter of collaboration ("Agreement") with Perpetuus Carbon Technologies Limited ("Perpetuus") pursuant to which GRAT and Perpetuus will develop and market material enhancing graphite derived graphenes and graphene hybrids for tire elastomers, whilst also exploring options to exploit polymer composites, energy capture and storage applications markets ("Project"). The Agreement contemplates the first Phase of the Project ("Phase 1"), with the other phases to be described in a joint venture agreement to be entered into between GRAT and Perpetuus. Pursuant to the Agreement, and as part of Phase 1, GRAT will purchase, and retain ownership, of three specialised process tooling chambers at an aggregate cost of 300,000 British Pounds. These specialized tooling chambers will be housed in Perpetuus' ex
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease20.4.2018 14:15 | Pressemelding
NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation (EMA/OD/013/18) for Abeona's gene therapy program ABO-202 for the treatment of subjects with neuronal ceroid lipofuscinosis, also known as Batten Disease, a fatal lysosomal storage disease that primarily affects the nervous system in children. ABO-202 is an adeno-associated virus developed to introduce a functional copy of the CLN1 gene into cells in order to restore the enzyme activity that is needed to break down certain lipopigment proteins that are deficient in patients with CLN1 disease. "This designation is an important step in our CLN1 program as it encourages us to proceed towards clinical development," st
Taconic Biosciences Licenses Easi-CRISPR Technology from the University of Nebraska20.4.2018 14:00 | Pressemelding
RENSSELAER, N.Y., April 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered mouse model and service solutions, has been granted a license to the Easi-CRISPR technology from the University of Nebraska. Easi-CRISPR was developed in the laboratories of Drs. Masato Ohtsuka (Tokai University in Japan), and Channabasavaiah Gurumurthy (University of Nebraska). The terms of the agreement include a world-wide, non-exclusive license to the technology, allowing Taconic rights to generate and sell rodent models generated via Easi-CRISPR. When compared to traditional CRISPR, Easi-CRISPR represents a significant advantage, allowing researchers to perform whole genetic insertions versus being limited to point mutations and constitutive knockouts. "Easi-CRISPR is the next progression of the revolutionary CRISPR/Cas technology. Combining the speed of CRISPR with larger genetic insertions allows complex projects typically requiring homologous recombinati
PayByPhone appoints Andreas Gruber as new President and CEO20.4.2018 00:19 | Pressemelding
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- PayByPhone, the global leader in mobile parking payments, today announced that it will appoint Andreas Gruber as president and Chief Executive Officer effective June 1st, 2018. Francis Dupuis, the former President and CEO, will take over a position in Germany with parent company Volkswagen Financial Services AG. To provide additional impetus to the PayByPhone board, two new board positions have been created and as a result Maggie Clay (CFO) and Catherine Scott (Legal Counsel) will be appointed effective June 1st, 2018. During his time at PayByPhone, Francis led the business through significant growth and organizational change and leaves the company well positioned for continued success. "We would like to thank Francis for his strong leadership and look forward to building on his experience within Volkswagen Financial Services," Gerd Künne, Vice-President of mobility unit at Volkswagen Financial Services, said. Francis is e
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom